


Precision Payloads:


Exploring ADC-Directed Therapies in
HER2-Mutant and Overexpressing Lung Cancer

This transcript has been edited for style and clarity and
includes all slides from the presentation.



Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

Joshua E. Reuss, MD



▶ Joshua E. Reuss, MD:

Hello, my name is Dr. Joshua Reuss. I'm a Thoracic Medical Oncologist at MedStar Georgetown University Hospital in the Georgetown Lombardi Comprehensive Cancer Center. And today, we're going to be discussing antibody-drug conjugate-directed therapies in *HER2*-mutated and overexpressing lung cancer. So, with that, let's begin.

HER2 as an Oncogenic Driver in Cancer

- Receptor tyrosine kinase encoded by erb-b2 receptor tyrosine kinase 2 (*ERBB2*) gene
- Activated via hetero- or homo-dimerization with other erbB family members, with subsequent activation of downstream signaling pathways (PI3K/AKT, MEK/ERK) that promote oncogenesis
- 3 types of alterations observed across solid tumor malignancies:
 - *HER2* gene mutations (targetable)
 - *HER2* gene amplification
 - *HER2* protein overexpression

Tumour types	HER2 amplification (%)	HER2 overexpression (%)	HER2 mutation (%)
Salivary gland	12-52	17-44	1
Breast	20	15-20	2
Stomach	11-16	20	3
Ovary	7	27	1
Uterus	4-69	18-80	2
Cervix	0.5-14	21	3
Lung	2-3	2.5	1-3
Biliary tract	5-15	20	2
Pancreas	2	26	<1
Colorectum	5.8	5	2
Bladder	8.6	12.4	9
Prostate	5.8-6	10	<1

Oh D-Y, Bang Y-J. *Nat Rev Clin Oncol*. 2020;17(1):33-48.
 AKT, protein kinase B; ERK, extracellular signal-regulated kinases; HER2, human epidermal growth factor receptor 2;
 MEK, mitogen-activated protein kinase kinase; PI3K, phosphoinositide 3-kinases.

▶ I think first, it's important to really review molecular testing, the clinical value and implications for HER2 testing in non-small cell lung cancer. So, first and foremost, HER2 is a rather diverse oncogenic driver in cancer in general. HER2 itself, it's a receptor tyrosine kinase encoded by the ERBB2 receptor tyrosine kinase 2, or ERBB2 gene.

This is activated via hetero and homodimerization with other family members with subsequent activation of downstream signaling pathways, PI3K/AKT/MEK activation, that promote oncogenesis and growth signaling.

There are 3 key types of alterations observed across solid tumors. One are *HER2*

gene mutations. This is what we most commonly are talking about in non-small cell lung cancer. *HER2* gene amplifications, and then *HER2* protein overexpression. The latter 2 we talk about more commonly in GI malignancies and breast cancer. In lung, we tend to think of *HER2* mutations occurring in about 1 to 3% of patients.

Genomic Testing in NSCLC

- Absolutely **critical** to clinical frontline decision-making in all stages, including resectable NSCLC and advanced NSCLC
- Comprehensive broad next-generation sequencing (NGS) is the gold standard, utilizing both tissue and blood-based testing platforms
- To assess **HER2 mutations** in NSCLC:
 - Comprehensive NGS is preferred
 - Can also be assessed via Sanger sequencing and targeted PCR techniques
- Important to **wait** for testing results before beginning systemic therapy in advanced NSCLC
 - Availability of genomic testing results has been shown to improve survival in advanced NSCLC
 - If clinical scenario warrants more immediate therapy, begin chemotherapy alone



Ettinger DS, et al. NCCN Guidelines. Non-Small Cell Lung Cancer. Version 3.2024.
Aggarwal et al. *JCO Precis Oncol.* 2023;7:e2300191.

► So, how do we look for these genomic alterations? Obviously, we need to test for these because if we don't test for them, we won't know that they're there. It is absolutely critical to perform next-generation sequencing and genomic testing, really in all stages of advanced non-small cell lung cancer ranging from resectable to advanced. Comprehensive broad next-generation sequencing is our gold standard, utilizing both tissue and blood-based platforms. To assess *HER2* mutations, again, comprehensive next-generation sequencing, or

NGS, is preferred. However, some older platforms, Sanger sequencing, and targeted PCR techniques also can be utilized. Now, it is absolutely important to wait for these results before beginning systemic therapy in advanced non-small cell lung cancer. There's actually been data to support that waiting for these results actually associated with improved survival in advanced non-small cell lung cancer. However, if you're in a clinical scenario where you just can't wait, someone has significant symptoms, signs of organ dysfunction. In that scenario, I will deploy chemotherapy

alone, which can oftentimes provide some cytoreduction allow you that time to wait for the results of the next-generation sequencing, before proceeding with appropriate molecular profile targeted therapy, whether that's a targeted treatment or a chemoimmunotherapy treatment. And in general, these next-generation sequencing tests, tissue tests, tend to take about 2 to 3 weeks, calendar weeks to come back, and then the liquid tests may be more like 7 to 10 calendar days.

Genomic Testing in NSCLC

NCCN Guidelines version 3.2024
Non-Small Cell Lung Cancer

CLINICAL PRESENTATION

- Establish histologic subtype with adequate tissue for molecular testing (consider rebiopsy or plasma testing if appropriate)
- Smoking cessation counseling
- Integrate palliative care

HISTOLOGIC SUBTYPE

- Adenocarcinoma
- Large cell
- NSCLC not otherwise specified (NOS)
- Squamous cell carcinoma

BIOMARKER TESTING

- Molecular testing, including:
 - EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2)
 - Testing should be conducted as part of broad molecular profiling
- PD-L1 testing (category 1)
- Consider molecular testing, including:
 - EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2)
 - Testing should be conducted as part of broad molecular profiling
- PD-L1 testing (category 1)



Adapted from Ettinger DS, et al. NCCN Guidelines. Non-Small Cell Lung Cancer, Version 3.2024. HER2, human epidermal growth factor receptor 2; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1.

So, this is taken from the NCCN Guidelines just talking about biomarker testing in advanced non-small cell lung cancer. You can see that next-generation sequencing molecular testing carries a Category 1 recommendation for adenocarcinoma large cell non-small cell lung cancer, and non-small cell lung cancer not otherwise specified. It is also part of the guidelines for squamous cell non-small cell lung cancer, though it does not carry the Category 1 recommendation. I will say though, that in my practice I do obtain next-generation sequencing on patients with squamous cell non-small cell lung cancer, as well.

Tissue Versus Plasma-Based Testing Considerations

Formalin-fixed Paraffin-embedded Tissue Tumor Testing

- Primary method of tumor testing
- Laboratories accept other specimen types
 - Cytopathology preparations not processed by FFPE methods
- Limitation: insufficient yield for molecular, biomarker, and histologic testing when minimally invasive techniques are used to obtain samples
 - Bronchoscopists and interventional radiologists should procure sufficient tissue to enable all appropriate testing

Circulating Tumor DNA (ctDNA) Testing

- Can be utilized in conjunction with tissue-based testing to achieve genotyping for recommended biomarkers
- Should not be used in lieu of a histologic tissue diagnosis
- High specificity, but significantly compromised sensitivity
 - Up to 30% false-negative rate
- Data support complementary ctDNA and tissue testing to reduce turnaround time and increase yield of targetable alteration detection



Ettinger DS, et al. NCCN Guidelines. Non-Small Cell Lung Cancer, Version 3.2024. FFPE, formalin-fixed paraffin-embedded; NSCLC, non-small cell lung cancer.


So, let's talk a bit further detail about tissue versus plasma-based testing considerations. So, for tissue, this is typically run on formalin-fixed paraffin-embedded samples. Typically cytopathology preparations, not processed by FFPE methods are not accepted, though I will say that for bronchoscopy samples, if you do get sufficient tissue with an FNA, as long as that can be put into a tissue block,

that usually is sufficient, and even sometimes highly cellular pleural effusions can be turned into blocks sufficient for testing as well. But primarily, you want to make sure that you're getting sufficient tissue and really trying to limit your IHC testing so as to preserve tissue for next-generation sequencing.

Circulating tumor DNA, or ctDNA testing. This is liquid testing that, I tend to obtain

upfront in conjunction with tissue testing. This also, very important platform to utilize. Oftentimes can come back quicker, and get you an answer sooner, when it comes to actionable driver mutations. And again, data does support the complementary use of ctDNA testing with tissue testing to reduce turn-around time and really increase your yield.

Algorithm for Incorporation of Liquid Testing Into Initial Work-up of Advanced NSCLC



Adapted from Aggarwal C, et al. *Nat Rev Clin Oncol.* 2021;18(1):56-62. ctDNA, circulating tumor DNA; NSCLC, non-small cell lung cancer.

► So, I think I told you my preferred method, which is to obtain tissue and liquid testing concurrently. This is one other algorithm that you can utilize. Whereas, if tissue testing is available for genotyping, and tissue is adequate, you can, for one, obtain concurrent testing as I do, or you could obtain the tissue testing and then wait. And if it's inadequate, then pursue liquid testing. Now, if tissue testing is inadequate, then one can, again, obtain

liquid testing first, followed by tumor tissue testing. They can obtain repeat biopsy and then do tissue, followed by liquid, though again, if your current tissue sample is insufficient, I do tend to recommend obtaining a liquid biopsy while concurrently scheduling a tissue biopsy if that is needed. Now, if tissue testing if tumor tissue is just unavailable period, plasma ctDNA, can be obtained upfront, again, with requesting the tissue testing if

needed. Or you could obtain the plasma tissue testing followed by biopsy, if the plasma testing is negative. But again, I do tend to like to, if I know the tissue is insufficient, I tend to want to at least schedule the tissue biopsy, because oftentimes I can get that answer back from the liquid biopsy before the tissue repeat biopsy is obtained, thereby really limiting the amount of time I'm waiting to start treatment.

Chairperson Perspectives


- Obtain molecular testing for every patient with NSCLC
- Ideally through NGS
- Can obtain both tissue and liquid (ctDNA) testing concurrently
- Perform testing before starting appropriate systemic therapy



ctDNA, circulating tumor DNA; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

► So, what do community clinicians need to keep in mind regarding genomic testing and why? I think really, the key take-home message here is really, every patient with advanced non-small cell lung cancer, and not only advanced, localized locally advanced. Really, across the spectrum of stages of non-small cell lung cancer should obtain molecular testing, ideally through next-generation sequencing testing. Again, I like to obtain both tissue and liquid concurrently, but really, one needs to be performing this testing before, starting appropriate systemic therapy in order to really best help our patients.

Treatment Strategies Targeting HER2 in Advanced NSCLC



Zhao J, Xia Y. JCO Precis Oncol. 2020;4:11-425.
HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; ORR, overall response rate; T-DM1, ado-trastuzumab emtansine; DS-8201a, fam-trastuzumab deruxtecan (T-DXd).

► So, with that, let's talk a little bit more detail about clinical decision making for *HER2*-mutated and overexpressing non-small cell lung cancer. Now, this figure here shows across the spectrum some of the therapies that have been tried over the years for *HER2*-altered non-small cell lung cancer. However, we're going to spend most of our time talking about what's in kind of the upper, midsection figure here, particularly, what's called DS-8201a, that was really the first name for what we now call trastuzumab deruxtecan, which is really broken through in advanced *HER2*-mutated non-small cell lung cancer.

Anatomy of an Antibody-Drug Conjugate (ADC)

Target: Antibody

- Target: selectively expressed or over-expressed on tumor cells
- Antibody: Human/humanized immunoglobulin
- IgG1 most common

Payload


- Highly potent cytotoxin including DNA damaging agents (PBD, calicheamicin), tubulin polymerization inhibitors (MMAE, DM1), and topoisomerase inhibitors (DXd)
- Drug-to-antibody ratio (DAR): number of payload moieties attached to a specific antibody

Linker

- Non-cleavable
 - Traffic to mature lysosomes for degradation
 - Limited "bystander effect"
- Cleavable
 - Cell physiology (pH, proteases, etc.) key to payload-linker uncoupling
 - Prominent "bystander effect"

Mechanism of Action

- Payload delivery, ADCC, complement-mediated cytotoxicity, inhibition of oncogenic drivers



Marks JA, et al. *Curr Oncol Rep*. 2022;24(12):1829-1841.
 ADCC, antibody-dependent cellular cytotoxicity; DM1, derivative of maytansine 1; DNA, deoxyribonucleic acid; DXd, DX-8951 derivative; HER2, human epidermal growth factor receptor 2; IgG1, immunoglobulin G1; MMAE, monomethyl auristatin-E; NSCLC, non-small cell lung cancer; PBD, pyrrolobenzodiazepines.


► So, what is an antibody-drug conjugate? Let's spend a little time homing in on that. There are really three key components here. One, the antibody, by nature the target that the antibody homes in on. Now, the target should be selectively expressed or overexpressed on tumor cells in order to prevent on-target, off-tumor toxicity. IgG-1 is the most common humanized, immunoglobulin utilized here. Now, the antibody is connected to a cytotoxic payload via a linker. Now, being a connection, the linker also helps to maintain stability of the antibody-drug conjugate in circulation. There are 2 key types of linkers, non-cleavable – these require trafficking to mature lysosomes for degradation, by nature of their biochemistry the compound has limited ability, the payload has limited

ability to then traverse across cell membranes and exert effects on neighboring cells. The so-called bystander effect, which can be important in the efficacy of these compounds. These types of linkers were primarily used in earlier generation antibody-drug conjugates, and they were used in T-DM1, as an example. The second are cleavable linkers. These rely on cell physiology, pH, proteases, etcetera for payload linker uncoupling, and because of their biochemistry, there is actually, typically, prominent bystander effect where the payload can diffuse across cell membranes and exert effect on neighboring cells. This is very, very important, tumors that have heterogeneous target expression and dense tumors that really require, permeation of that payload to affect the cancer cells. Now,

the payload in these current generation ADCs is primarily a highly potent cytotoxin, such as a DNA-damaging agent, or topoisomerase inhibitor. These are almost, you could think of them like chemotherapeutics that are incredibly potent in the picomolar concentration. A related important aspect of this is called the drug-to-antibody ratio, or DAR. These are the number of payload moieties that are attached to a specific antibody. And the mechanism of action of how these compounds work primarily with payload delivery. However, antibody-dependent cell cytotoxicity, complement-mediated cytotoxicity, and in select cases, inhibition of oncogenic drivers, are all postulated as contributing to the anti-tumor effect of these compounds.

Rationale for ADCs in *HER2*-Mutated NSCLC

- Receptor internalization upon ADC binding is key to efficacy
- *HER2* mutations increase receptor internalization and ADC cytotoxic activity compared to *HER2*-wild type in preclinical studies




► So, what is the rationale for antibody-drug conjugates in *HER2*-mutated non-small cell lung cancer? This is actually quite elegant work that came out of Bob Li's lab at Memorial Sloan Kettering, which showed that in *HER2*-mutated cancers compared to wild-type, there's actually increased internalization of the *HER2* receptor which preclinically leads to increased internalization of ADC compounds which is showing, really, the rationale for how these compounds can be utilized in *HER2*-mutated non-small cell lung cancer.



Li BT, et al. *Cancer Discov.* 2020;10(5):674-687.
ADC, antibody-drug conjugate; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer.

Ado-Trastuzumab Emtansine (T-DM1)



T-DM1

- *HER2*-targeted ADC of trastuzumab conjugated to the anti-microtubule agent DM1 via a non-cleavable linker
- Approved as subsequent-line therapy in advanced *HER2*+ breast cancer
- Carries category 2A recommendation for subsequent line therapy in advanced *HER2*-mutated NSCLC

- Efficacy signals observed in *HER2*-mutated and -amplified NSCLC
- Phase II basket study of 49 pts w/ previously treated advanced NSCLC: ORR 51%, mPFS 5 months
 - Dose: 3.6 mg/kg IV over 90 minutes on day 1 of each 21-day cycle until disease progression or unmanageable toxic effects
 - *HER2*-mutated (n=28): ORR 50%
 - *HER2*-amplified (n=11): ORR 50%
 - *co-HER2-mutated/amp* (n=10): ORR 50%
- Multiple phase II trials have demonstrated little benefit for T-DM1 in NSCLC with *HER2* overexpression
 - Only observed responses were in patients with either concurrent *HER2* amplification or *HER2* mutations
- Major toxicities: cytopenias, fatigue, elevated LFTs, infusion reactions



Li BT, et al. *Cancer Discov.* 2020;10(5):674-687. Hotta K, et al. *J Thorac Oncol.* 2018;13(2):273-279. Peters S, et al. *Clin Cancer Res.* 2019;25(1):64-72.
ADC, antibody-drug conjugate; DM1, derivative of maytansine 1; *HER2*, human epidermal growth factor receptor 2; IV, intravenous; LFT, liver function test; mPFS, median progression-free survival; NSCLC, non-small cell lung cancer; ORR, overall response rate; T-DM1, ado-trastuzumab emtansine.


► So, the first antibody-drug conjugate that was shown to have efficacy in *HER2*-altered non-small cell lung cancer was ado-trastuzumab emtansine, or T-DM1. This is composed of anti-*HER2* monoclonal trastuzumab, conjugated to the anti-microtubule agent DM1 via a non-cleavable linker. This was an agent that has been approved in subsequent therapy as advanced *HER2*-positive breast cancer. And importantly, efficacy signals are observed in *HER2*-mutated

and amplified non-small cell lung cancer. This is primarily from a Phase 2 basket study of 49 patients, that have previously-treated advanced non-small cell lung cancer, where a response rate of 51%, with a median progression free survival of 5 months was observed. As you can see here in some of the breakdown of the data, responses were observed in both *HER2*-mutated and *HER2*-amplified non-small cell lung cancer, although interestingly,


very minimal benefit was seen in those with *HER2*-overexpressing non-small cell lung cancer in multiple Phase 2 studies. Key toxicities of this compound include cytopenias, fatigue, elevated LFTs, and infusion reactions, and the component actually carries a category 2a recommendation for subsequent line therapy in advanced *HER2*-mutated non-small cell lung cancer, though of note, is not formally approved, by the FDA in this setting.

T-DM1 in *HER2*-Altered NSCLC

HER2-overexpressed NSCLC



HER2-mutated and/or *HER2*-amplified




*positive *HER2* amplification

► This is just a visual depiction of the figures showing the difference in response rates for T-DM1 in *HER2*-altered non-small cell lung cancer, between *HER2*-overexpressing non-small cell lung cancer and then *HER2*-mutated or *HER2*-amplified. And really efficacy observed was primarily in those with *HER2*-mutated, or *HER2*-amplified non-small cell lung cancer.



Peters S, et al. Clin Cancer Res. 2019;25(1):64-72. Li BT, et al. Cancer Discov. 2020;10(5):674-687.
HER2, *erbB2* receptor tyrosine kinase 2; *HER2*, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NE, not evaluable; NSCLC, non-small cell lung cancer; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; T-DM1, ado-trastuzumab emtansine.

Trastuzumab Deruxtecan (T-DXd)



T-DXd

- *HER2*-targeted ADC of trastuzumab conjugated to deruxtecan (DXd) via cleavable linker with DAR of 8
- Elicits significant bystander effect, supporting use in tumors with heterogeneous *HER2*-expression
- FDA approvals in advanced *HER2*-positive and *HER2*-low breast cancer, *HER2*-positive gastric or GE junction adenocarcinoma
- Carries category 2A recommendation as the only preferred subsequent line therapy in advanced *HER2*-mutated NSCLC

► But moving on to really what was much more exciting in the field, was the emergence of the next-generation antibody-drug conjugate trastuzumab deruxtecan, or T-DXd, in advanced non-small cell lung cancer. So, T-DXd is composed of the *HER2*-targeted antibody trastuzumab conjugated to the, payload of deruxtecan, or T-DXd via cleavable linker with the drug-to-antibody ratio of 8. Now, because of this cleavable linker, as I alluded to earlier, this compound is able to elicit significant bystander effect supporting its use in tumors with heterogeneous *HER2* expression. And prior to its accelerated approval in non-small cell lung cancer, this compound has been approved in patients with *HER2*-positive and *HER2*-low breast cancer, *HER2*-positive gastric or gastroesophageal junction adenocarcinoma.



Smit EF, et al. J Clin Oncol. 2020;38(15_suppl):9504.
 ADC, antibody-drug conjugate; DAR, drug-antibody ratio; GE, gastroesophageal; *HER2*, human epidermal growth factor receptor 2; IgG1, immunoglobulin G1; T-DXd, trastuzumab deruxtecan.


T-DXd in Advanced *HER2*-Mutated NSCLC

DESTINY-Lung01 Study Design

Multicenter, international, 2-cohort phase 2 trial (NCT03505710)

Key eligibility criteria

- Unresectable/metastatic nonsquamous NSCLC
- Relapsed from or is refractory to standard treatment
- Measurable disease by RECIST v1.1
- Asymptomatic CNS metastases at baseline[§]
- ECOG PS of 0 or 1
- Locally reported *HER2* mutation (for Cohort 2)[¶]



Primary end point

- Confirmed ORR by ICR[¶]

Secondary end points

- DOR
- PFS
- OS
- DCR
- Safety

Exploratory end point

- Biomarkers of response

[¶]Patients with asymptomatic brain metastases not requiring ongoing steroid or anticonvulsant therapy were allowed to enroll [§]*HER2* mutation documented solely from a liquid biopsy could not be used for enrollment [¶]*HER2* overexpression without known *HER2* mutation was assessed by local assessment of archival tissue and centrally confirmed [¶]Per RECIST v1.1



Li BT, et al. ESMO 2021, Abstract LBA45.
 CNS, central nervous system; DCR, disease control rate; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; *HER2*, human epidermal growth factor receptor 2; ICR, independent central review; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PS, performance status; q3w, every 3 weeks; RECIST v1.1, Response Evaluation Criteria in Solid Tumours version 1.1.

► So, what data do we have in, advanced non-small cell lung cancer? Now, the first data that emerged was from the DESTINY-Lung01 study. This was a large multi-center international 2-cohort Phase 2 study that looked at patients with unresectable metastatic previously treated non-squamous non-small cell lung cancer and enrolled them into 1 of 2 key cohorts. Cohort 1 was in *HER2*-overexpressing non-small cell lung cancer, and cohort 2 wherein patients with activating *HER2* mutations, with a primary endpoint of objective response rate.

T-DXd Demonstrated Promising Activity in DESTINY-Lung01 in Patients With *HER2*-Mutated NSCLC


Table 2. Response to Trastuzumab Deruxtecan as Assessed by Independent Central Review.

Response Assessment	Patients (n-%)
Confirmed objective response*	
No. of patients	50
Percentage of patients (95% CI)	55 (44-65)
Best response — no. (%)	
Complete response	1 (1)
Partial response	49 (54)
Stable disease	34 (37)
Progressive disease	3 (3)
Response could not be evaluated	4 (4)
Disease control [†]	
No. of patients	84
Percentage of patients (95% CI)	92 (85-97)
Median time to response (range) — mo [‡]	1.5 (1.0-9.7)
Median duration of response (95% CI) — mo [‡]	9.3 (5.3-14.7)

* Confirmed objective response was assessed by independent central review on the basis of the Response Evaluation Criteria in Solid Tumors, version 1.1.

[†] Disease control was defined as complete response, partial response, or stable disease at 6 weeks with no progression.

[‡] Analysis of time to response and duration of response included only the patients with a confirmed objective response.



Activity observed across *HER2* mutation subtypes and irrespective of *HER2*amp or *HER2* expression status




Li BT, et al. ESMO 2021, Abstract LBA45.
HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; T-DXd, trastuzumab deruxtecan.

► Now, homing in on those with *HER2* mutations, this was really exciting data when it was first released here, showing a response rate of 55% in those with *HER2* mutations. Importantly, activity was observed across *HER2* mutation subtypes and irrespective of concurrent *HER2* amplification, or *HER2* expression status, with a median duration of response of 9.3 months.

DESTINY-Lung02 Trial: Study Design

Phase 2 Randomized, Non-Comparative Trial




Jänne P, et al. WCLC 2023. Abstract MA13.10.
 BICR, blinded independent central review; DCR, disease control rate; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; INV, investigators; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PS, performance status; Q3W, every 3 weeks; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; T-DXd, trastuzumab deruxtecan.

► Now, while this was the first data that was released, what the data that actually led the trial that led to the approval of this compound in advanced HER2-mutated non-small cell lung cancer was the DESTINY-Lung02 trial. Here we showed the design of this study. This study was randomized 2 to 1 in a non-comparative study of T-DXd 5.4 mgs/kg every 3 weeks, or 6.4 mgs/kg every 3 weeks, with the primary endpoint of a confirmed objective response rate.

Similar Efficacy Observed at Either Dose in DESTINY-Lung02

	T-DXd 5.4 mg/kg Once Every 3 Weeks (n = 102)	T-DXd 6.4 mg/kg Once Every 3 Weeks (n = 50)
Response Assessment by BICR		
Confirmed ORR, No. (%)	50 (49.0)	28 (56.0)
95% CI	39.0 to 59.1	41.3 to 70.0
Best confirmed overall response, No. (%)		
CR	1 (1.0)	2 (4.0)
PR	49 (48.0)	26 (52.0)
SD	45 (44.1)	18 (36.0)
PD	4 (3.9)	2 (4.0)
Nonevaluable ^a	3 (2.9)	2 (4.0)
DCR, No. (%)	95 (93.1)	46 (92.0)
95% CI	86.4 to 97.2	80.8 to 97.8
DoR, months, median (95% CI)	16.8 (6.4 to NE)	NE (8.3 to NE)
TTIR, months, median (range)	1.8 (1.2-7.0)	1.6 (1.2-11.2)
Follow-up, months, median (range)	11.5 (1.1-20.6)	11.8 (0.6-21.0)



► This is the key data from this study. When comparing the 5.4 to 6.4 milligram per kilogram dose, very similar response rates, 49% with 5.4, 56% with 6.4 mgs/kg, with clinically similar progression free survival and overall survival.

Goto K, et al. J Clin Oncol. 2023;41(31):4852-4863. Jänne P, et al. WCLC 2023. Abstract MA13.10.
 CR, complete response; DCR, disease control rate; DoR, duration of response; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; T-DXd, trastuzumab deruxtecan; TTIR, time to initial response.

Final Results of DESTINY-Lung02 in Patients with Previously Treated HER2-mutant NSCLC

	T-DXd 5.4 mg/kg N=102	T-DXd 6.4 mg/kg N=50
cORR, %	50.0	56.0
Median DoR, mo	12.6	12.2
Median PFS, mo	10.0	12.9
Median OS, mo	19.0	17.3


► And more recently, we saw the final results of this study presented at ASCO 2024 this year, which, very similar numbers. Though, of note, the final median survival in the study showed a T-DXd 5.4 mg/kg dose survival of 19 months. And at the 6.4 mg/kg dose of 17.3 months. So, maybe a numerically slightly higher survival with the lower dose, but I think the key take-home point here is, from an efficacy standpoint, very similar.



Jänne PA, et al. *J Clin Oncol*. 2024;42(suppl 16):8543.
 cORR, confirmed overall response rate; DoR, duration of response; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan.

Anti-Tumor Activity of T-DXd 5.4 mg/kg in Advanced HER2-Mutated NSCLC

Best Percentage Change in Tumor Size by BICR With T-DXd 5.4 mg/kg (N=102)



► This is just another figure showing the efficacy at that 5.4 mg/kg dose, and as was observed in DESTINY-Lung01, efficacy observed irrespective of the type of HER2 mutation, and irrespective of concurrent HER2 amplification or overexpression status with an objective response rate of 49%. Though again, in the more recent presentation at ASCO, this response rate, was noted at 50%.



Goto K, et al. *J Clin Oncol*. 2023;41(31):4852-4863. Jänne P, et al. WCLC 2023. Abstract MA13.10.
 BICR, blinded independent central review; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; ORR, overall response rate; T-DXd, trastuzumab deruxtecan.

Safety Profile of T-DXd Is More Favorable at 5.4 mg/kg Compared to 6.4 mg/kg Every 3 Weeks

Adjudicated Drug-Related ILD

Preferred Term	T-DXd 5.4 mg/kg Once Every 3 Weeks (n = 101) ^a No. (%)		T-DXd 6.4 mg/kg Once Every 3 Weeks (n = 50) ^a No. (%)		Adjudicated as drug-related ILD	T-DXd 5.4 mg/kg N = 101 ^a	T-DXd 6.4 mg/kg N = 50 ^a
	Any Grade	Grade ≥ 3	Any Grade	Grade ≥ 3			
Nausea	60 (59.4)	4 (4.0)	49 (98.0)	3 (6.0)			
Neutropenia ^b	43 (42.6)	19 (18.8)	39 (78.0)	18 (36.0)			
Fatigue ^b	45 (44.6)	8 (7.9)	25 (50.0)	5 (10.0)			
Decreased appetite	40 (39.6)	2 (2.0)	25 (50.0)	2 (4.0)			
Anemia ^b	37 (36.6)	11 (10.9)	26 (52.0)	8 (16.0)			
Vomiting	32 (31.7)	3 (3.0)	22 (44.0)	1 (2.0)			
Constipation	37 (36.6)	1 (1.0)	16 (32.0)	0			
Leukopenia ^b	29 (28.7)	5 (5.0)	17 (34.0)	8 (16.0)			
Thrombocytopenia ^b	38 (37.7)	6 (5.9)	14 (28.0)	5 (10.0)			
Diarrhea	23 (22.8)	1 (1.0)	18 (36.0)	2 (4.0)			
Alpecia	22 (21.8)	0	17 (34.0)	0			
Transaminases increased ^c	22 (21.8)	3 (3.0)	10 (20.0)	0			

Adjudicated as drug-related ILD	T-DXd 5.4 mg/kg N = 101 ^a	T-DXd 6.4 mg/kg N = 50 ^a
Any grade, n (%)	13 (12.9)	14 (28.0)
Grade 1	4 (4.0)	4 (8.0)
Grade 2	7 (6.9)	9 (18.0)
Grade 3	1 (1.0)	0
Grade 4	0	0
Grade 5	1 (1.0)	1 (2.0)

Based on these data, T-DXd 5.4 mg/kg IV q3w was granted accelerated FDA approval for the treatment of advanced *HER2*-mutated NSCLC after progression on prior therapy



Goto K, et al. *J Clin Oncol*. 2023;41(31):4852-4863. Jänne P, et al. *WJCO*. 2023. Abstract MA13.10.
HER2, human epidermal growth factor receptor 2; *ILD*, interstitial lung disease; *IV*, intravenous;
NSCLC, non-small cell lung cancer; T-DXd, trastuzumab deruxtecan.

► And again, similar efficacy, but importantly, much more favorable safety profile at the 5.4 mg/kg dose. You could see here, both in terms of toxicities that we commonly associate with chemotherapy, such as, cytopenias, nausea, fatigue, where that was numerically lower. In addition, grade 3 or higher treatment related adverse events were overall lower at the 5.4 mg/kg dose. And then, importantly, drug-related ILD was lower shown in the publication from last year. Any-grade ILD of 12.9% at 5.4 mg/kg dose, compared to 28% more recently at ASCO. This was updated to 14.9 versus 32%. Primarily these were lower grade AEs, grade 1 or 2. But importantly, again, the rate was over half at the 5.4 mg/kg dose, really further supporting it's accelerated approval in patients with advanced *HER2*-mutated non-small cell lung cancer with progression on prior therapy.

T-DXd FDA Approval in *HER2*-Mutant NSCLC

- August 2022: FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic NSCLC whose tumors have activating *HER2/ERBB2* mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy
 - First drug approved for *HER2*-mutant NSCLC
- FDA also approved the Life Technologies Corporation's OncoPrint™ Dx Target Test (tissue) and the Guardant Health, Inc.'s Guardant360® CDx (plasma) as companion diagnostics
 - If no mutation is detected in a plasma specimen, the tumor tissue should be tested
- Recommended dosage for lung cancer:
 - 5.4 mg/kg
 - Intravenous infusion
 - Once every 3 weeks (21-day cycle)
 - Until disease progression or unacceptable toxicity



FDA.gov. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung-erbb2-erb-b2-receptor-tyrosine-kinase-2-her2-human-epidermal-growth-factor-receptor-2-nsclc-non-small-cell-lung-cancer-t-dxd-trastuzumab-deruxtecan>.

► So, in August of 2022, the FDA granted an accelerated approval for trastuzumab deruxtecan in patients with advanced *HER2*-mutated non-small cell lung cancer who have received prior systemic therapy. This was the first drug approval for *HER2*-mutated non-small cell lung cancer. And again, the recommended dose is 5.4 milligrams per kilogram once every 3 weeks.


CNS Efficacy of T-DXd in *HER2*-Mutated NSCLC

Pooled CNS efficacy data from DESTINY-Lung01 and DESTINY-Lung02 Studies

Measurable BM at Baseline

	T-DXd 5.4 mg/kg DL-02 BM n = 14	Pooled T-DXd 6.4 mg/kg DL-01 <i>HER2</i> m/DL-02 BM n = 30
IC-cORR, n (%) ^a	7 (50.0)	9 (30.0)
95% CI ^b	23.0-77.0	14.7-49.4
CR	3 (21.4)	0
PR	4 (28.6)	9 (30.0)
SD	6 (42.9)	13 (43.3)
PD	1 (7.1)	4 (13.3)
NE ^c	0	2 (6.7)
Missing	0	2 (6.7)
IC-DCR, n (%) ^a	13 (92.9)	22 (73.3)
95% CI ^b	66.1-99.8	54.1-87.7
IC-DoR, months ^d		
Median, (95% CI) ^e	9.5 (3.6-NE)	4.4 (2.9-10.2)

12/14 (86%) patients with measurable BM receiving T-DXd 5.4 mg/kg and 21/27 (78%) in the pooled 6.4 mg/kg group experienced a reduction in brain lesion size from baseline as their best overall response



Now, one might think that based off of the construct of these compounds, that they may have limited ability to traverse into the CNS illicit effects there. But as this data here highlights this actually is likely false and that we actually have observed significant CNS efficacy of T-DXd in *HER2*-mutated non-small cell lung cancer. This is pooled CNS efficacy data from DESTINY-Lung-01 and DESTINY-LUNG-02, including in patients that received no prior radiation treatment, there is efficacy in the CNS, including a very favorable CNS disease control rate and duration of response.



LI BT, et al. ESMO 2022, Abstract 1321MO.
BM, brain metastases; CNS, central nervous system; CR, complete response; *HER2*, human epidermal growth factor receptor 2; IC-DCR, intracranial disease control rate; IC-DoR, intracranial duration of response; NE, not evaluable; NSCLC, non-small cell lung cancer; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; T-DXd, trastuzumab deruxtecan.


T-DXd in Advanced NSCLC With *HER2* Overexpression

DESTINY-Lung01 Study Design

Multicenter, international, 2-cohort phase 2 trial (NCT03505710)

Key eligibility criteria

- Unresectable/metastatic nonsquamous NSCLC
- Relapsed from or is refractory to standard treatment
- Measurable disease by RECIST v1.1
- Asymptomatic CNS metastases at baseline^a
- ECOG PS of 0 or 1
- Locally reported *HER2* mutation (for Cohort 2)^b



Primary end point
• Confirmed ORR by ICR^c

Secondary end points
• DOR
• PFS
• OS
• DCR
• Safety

Exploratory end point
• Biomarkers of response

^aPatients with asymptomatic brain metastases not requiring ongoing steroid or anticonvulsant therapy were allowed to enroll ^b*HER2* mutation documented solely from a liquid biopsy could not be used for enrollment ^c*HER2* overexpression without known *HER2* mutation was assessed by local assessment of archival tissue and centrally confirmed ^dPer RECIST v1.1



LI BT, et al. ESMO 2021, Abstract 1BA45.
CNS, central nervous system; DCR, disease control rate; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; *HER2*, human epidermal growth factor receptor 2; ICR, independent central review; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PS, performance status; q3w, every 3 weeks; RECIST v1.1, Response Evaluation Criteria in Solid Tumours version 1.1.

Now, as I mentioned earlier, in DESTINY-Lung-01, there was also a cohort of patients that were included that had *HER2*-overexpressing non-small cell lung cancer, including IHC of either 3 or 2 plus.

Activity of T-DXd in Advanced NSCLC With HER2 Overexpression Is More Modest

	Cohort 1 (6.4 mg/kg) N = 40	Cohort 1a (5.4 mg/kg) N = 44	No. of responders	Confirmed ORR (95% CI)	Confirmed ORR (95% CI)
ORR by ICR, % (95% CI)	26.5 (15.0-41.1)	34.1 (20.1-50.6)	Cohort 1 (all patients)	13/49	26.5 (15.0-41.1)
CR	0	4.9	HER2 IHC 3+	2/10	20.0 (2.5-55.6)
PR	26.5	29.3	HER2 IHC 2+	11/39	28.2 (15.0-44.9)
SD	42.9	43.9	Cohort 1a (all patients)	14/41	34.1 (20.1-50.6)
PD	22.4	9.8	HER2 IHC 3+	8/17	52.9 (27.8-77.6)
NE	8.2	12.2	HER2 IHC 2+	5/24	20.8 (7.1-42.2)
DCR, % (95% CI)	69.4 (54.6-81.8)	78.0 (62.4-89.4)			
DoR, median (95% CI), months	5.8 (4.3-NE)	6.2 (4.2-9.8)			

► There was efficacy observed, although, probably, I would say less prominent, or more modest efficacy response rates ranging from 26 to 34%. And given the majority of patients enrolled were at the 2+ IHC level, it's really hard to delineate overall response between those with 3+ and 2+, though perhaps, maybe numerically slightly higher or at the 3+ level.



Smit EF, et al. ESMO 2022. Abstract 975P; Smit EF, et al. J Clin Oncol. 2024;42(4):438-454.
 CR, complete response; DCR, disease control rate; DOR, duration of response; HER2, human epidermal growth factor receptor 2; ICR, independent central review; IHC, immunohistochemistry; NE, not evaluable; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; T-DXd, trastuzumab deruxtecan.

T-DXd FDA Accelerated Approval in Metastatic HER2+ Solid Tumors

- April 2024: T-DXd granted accelerated approval in the U.S. for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options
 - Based on data from DESTINY-PanTumor02 trial and DESTINY-Lung01 trial
 - DESTINY-PanTumor02:
 - > ORR: 51.4%
 - > Median DOR: 19.4 months
 - DESTINY-Lung01:
 - > ORR: 52.9%
 - > Median DOR: 6.9 months

► So, based off of this data and data from the DESTINY-PanTumor02 study, the FDA actually granted accelerated approval to T-DXd in patients with advanced unresectable solid tumors with HER2 overexpression defined by IHC 3+, who have received prior therapy and have no other satisfactory alternative treatments. Alluded to the DESTINY-Lung01, study data and then the PanTumor-02 response rates there at 51.4% with the median duration of response of 19.4 months.



FDA.gov. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2>.
 DOR, duration of response; HER2, human epidermal growth factor receptor 2; ORR, objective response rate; T-DXd, trastuzumab deruxtecan.

Chairperson Perspectives

- T-DXd now FDA-approved in *HER2*-mutated NSCLC
 - In patients who have experienced disease progression on prior systemic therapy
 - 5.4 mg/kg dose
- T-DXd now FDA-approved in previously treated *HER*-overexpressing solid tumors
 - More data in NSCLC needed
- Frontline therapy: follow traditional treatment algorithm



FDA, Food and Drug Administration; *HER2*, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; T-DXd, trastuzumab deruxtecan.

► So, what are the key perspectives from this data? What is most practice-changing? I think the number one most practice-changing here is really DESTINY-Lung02, trastuzumab deruxtecan in *HER2*-mutated non-small cell lung cancer. You know, this is now a treatment option for patients who have experienced disease progression on prior systemic therapy. The final response, duration of response, progression free and overall survival data from this study supported use of the 5.4 milligram per kilogram dose over the 6.4 milligram per kilogram dose given the favorable safety profile here. Regarding the data on *HER2*-overexpressing non-small cell lung cancer, it's excellent to have another option, though I do want to see more data to better assess how this compares to our other subsequent line

therapy such as docetaxel, as well as to see what's really driving that response. Is it truly the *HER2* overexpression, is it concurrent amplification, or some other factors that might be leading responses in select patients? So, I think these are all important things to keep in mind. Regarding frontline therapy for *HER2*-mutated non-small cell lung cancer I think it's up to the clinician whether to pursue chemotherapy alone or to add in immunotherapy. The data is mixed on use of immunotherapy in this population, but again, I think that really should be deferred to the treating clinician for *HER2*-mutated non-small cell lung cancer. For those with *HER2*-overexpressing non-small cell lung cancer. It's important to keep in mind that these patients should be treated, along traditional treatment algorithm

for those without driver mutations, so really, following a treatment algorithm of an immunotherapy backbone approach, if that's appropriate for a particular patient.

Now, what about other data from ASCO find exciting here? So, there are some future targeted therapies to keep your eye out on. One is zongertinib that was showed in the BEAMION-Lung 01 study. And importantly, in early data in 41 patients with advanced non-small cell lung cancer, a response rate of 44% was observed with a median duration of 15.8 months. in addition, across enrolled cohorts in this study, patients who had received prior trastuzumab deruxtecan saw a response rate of fixed 36%. So, it's important to note that there are emerging targeted therapies out there that hopefully will make a major impact for our patients.

Ongoing T-DXd Clinical Trials

Trial	Phase	Treatment	Setting
DESTINY-Lung03 (NCT04686305)	1b	T-DXd and immunotherapy (durvalumab, MEDI5752) with or without chemotherapy	First-line treatment of patients with advanced or metastatic nonsquamous NSCLC and HER2 overexpression
DESTINY-Lung04 (NCT05048797)	3	T-DXd vs SOC (platinum [investigator's choice of cisplatin or carboplatin], pemetrexed, and pembrolizumab)	First-line treatment of patients with unresectable, locally advanced (not amenable to curative therapy), or metastatic nonsquamous NSCLC with HER2 exon 19 or 20 mutations (detected in tissue or circulating tumor DNA)
DESTINY-Lung05 (NCT05246514)	2	T-DXd	Treatment of patients with HER2 mutant NSCLC who have disease progression on or after at least one line of treatment (2L+)

► So, these are other ongoing trials of trastuzumab deruxtecan in non-small cell lung cancer. DESTINY-Lung03 is looking at the combination of T-DXd with other immunotherapies with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer with HER2 overexpression. DESTINY-Lung-04 is a Phase 3 trial looking at T-DXd versus standard-of-care frontline setting for patients with advanced *HER2*-mutated non-small cell lung cancer. And the DESTINY-Lung-05 is a Phase 2 study looking at T-DXd in patients with *HER2*-mutated non-small cell lung cancer who have disease progression on or after at least one line of treatment.



Blanchard D, et al. *Ann Oncol*. 2023;34(suppl 2):S848-S849. Li BT, et al. *J Clin Oncol*. 2022;40(16_suppl):TPS9137. ClinicalTrials.gov. NCT05246514. 2L, second line; DNA, deoxyribonucleic acid; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; T-DXd, trastuzumab deruxtecan.

Can We Bring T-DXd Into the Frontline Management of Patients With Advanced *HER2*-Mutated NSCLC?

Phase 3 Randomized DESTINY-Lung04 Trial (NCT05048797)

Patient population (N=264)

- Unresectable, locally advanced (not amenable to curative therapy), or metastatic nonsquamous NSCLC with *HER2* exon 19 or 20 mutations*
- Naive to systemic therapy in the locally advanced or metastatic setting
- No known other targetable oncogenic mutations/alterations



Randomization
1:1

Arm 1: T-DXd^b

Arm 2: Standard of care^b
platinum^c (cisplatin or carboplatin)
+ pemetrexed
+ pembrolizumab

Primary Endpoint: PFS

* *HER2* mutations may be detected in tissue or ctDNA.
^b Crossover is not permitted.
^c Investigator's choice of cisplatin or carboplatin.


► So, a little bit more on DESTINY-Lung-04, is really asking is, can we bring T-DXd into the front-line treatment of patients with advanced *HER2*-mutated non-small cell lung cancer? So, this study is a Phase 3 randomized trial randomizing patients 1 to 1 to either T-DXd or to standard-of-care with platinum doublet chemotherapy plus pembrolizumab. And again, this includes patients, with activating *HER2* mutations advanced non-small cell lung cancer that is treatment naive.



Li BT, et al. ASCO 2022. Abstract TPS9137. ctDNA, circulating tumor DNA; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan.

Can We Bring T-DXd Into the Management of Advanced NSCLC With HER2 Overexpression?

Phase 1b DESTINY-Lung03 trial of T-DXd combination therapy in NSCLC w/ HER2 overexpression (NCT04686305)



► DESTINY-Lung03, so again, this is a multi-arm trial looking at various combinations of T-DXd with immunotherapies, with or without platinum, in patients with unresectable locally advanced or metastatic HER2-overexpressing non-squamous non-small cell lung cancer that is treatment naive.



Planchard D, et al. ESMO 2023. Abstract 15071P.
 ECOG: Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HER2-OE, HER2 overexpression; NSCLC, non-small cell lung cancer; T-DXd, trastuzumab deruxtecan; WHO, World Health Organization.

What Role Does Immunotherapy Play in HER2-Mutated NSCLC?

Anti-PD(L)1 Monotherapy in HER2-mutated NSCLC

Study	Sample size	ORR	mDoR	mPFS	mOS
Mazieres et al. ¹	29	7%	-	2.5mo	20.3mo
Guisier et al. ²	23	27%	15.2mo	2.2mo	20.4mo

Should anti-PD(L)1 therapy be incorporated into the frontline management of advanced HER2-mutated NSCLC?

- Controversial, no prospective randomized data
- NCCN guidelines recommend following approach for advanced NSCLC without driver mutation³ (see next slide)
- In clinical practice, would not routinely administer frontline anti-PD(L)1 monotherapy
- Decision to add anti-PD(L)1 immunotherapy to platinum-doublet chemotherapy should be patient-specific and incorporate factors such as smoking status, co-mutational profile, patient comorbidities, etc




1. Mazieres J, et al. Ann Oncol. 2019;30(8):1321-1328. 2. Guisier F, et al. J Thorac Oncol. 2020;15(4):629-636. 3. Estinger DS, et al. NCCN Guidelines. Non-Small Cell Lung Cancer. Version 3.2024.
 HER2, human epidermal growth factor receptor 2; mDoR, median duration of response; mOS, median overall survival; mPFS, median progression-free survival; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer; ORR, overall response rate.

► So, I alluded to this a little bit earlier, but what role does immunotherapy play in HER2-mutated non-small cell lung cancer? So, this is just, a table summarizing some small retrospective studies talking about, talking about anti-PD-1 and PD-L1 monotherapy in HER2-mutated non-small cell lung cancer. And you could see that overall responses not particularly robust. But the real question here is, should we incorporate anti-PD1 and PD-L1 therapy with platinum doublet chemotherapy in the frontline management of advanced


HER2-mutated non-small cell lung cancer?

Now again, as I alluded to earlier, this is really clinician decision. I know many colleagues where they would do platinum doublet chemotherapy alone and others do incorporate immunotherapy. I think you can make this decision as well on a case-by-case basis looking at the molecular profile. Is there anything, concurrent alterations there that would support benefit of immunotherapy? Is patient of prior smoker? Or are there

any clear contraindications to immunotherapy, such as significant, autoimmune disease? So, I think all these things should be taken into consideration, when considering addition of immunotherapy to platinum doublet chemotherapy in the frontline treatment of advanced HER2-mutated non-small cell lung cancer. So, I will say that I typically do steer away from PD-1 monotherapy or immunotherapy alone in patients with HER2-mutated non-small cell lung cancer.



► These are the NCCN guidelines for *HER2*-mutated non-small cell lung cancer. And just to highlight that they do show that one should follow frontline setting the adenocarcinoma or squamous cell carcinoma treatment approach. And then on progression considering T-DXd or trastuzumab emtansine, T-DM1, and then following progression there on appropriate standard therapy.



► But as I alluded to earlier, this is kind of my approach where I would utilize platinum doublet chemotherapy with or without a PD-1/PD-L1 immunotherapy, again, with a patient-specific decision-making there, looking at computational profile, smoking status, etcetera, following disease progression. That's when I would consider T-DXd, and after that, assess subsequent line chemotherapy. T-DM1 after T-DXd, there's not a lot of data there, and overall when tried, minimal response is observed when T-DM1 followed T-DXd.

Perspectives on Management of Advanced NSCLC With HER2 Overexpression

- T-DXd now has a **tumor agnostic approval** for unresectable or metastatic HER2-positive (IHC3+) solid tumors (DESTINY-Lung01 trial)
- NCCN Guidelines now include T-DXd as a systemic therapy option for advanced or metastatic NSCLC (subsequent and progression) for patients with PS 0-2 for adenocarcinoma, large cell, NSCLC NOS, and squamous cell carcinoma, only in patients whose tumors have HER2 overexpression (IHC3+)



Smit EF, et al. *Lancet Oncol.* 2024;25:439-454. Ettinger DS, et al. NCCN Guidelines. Non-Small Cell Lung Cancer. Version 3.2024. HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; NOS, not otherwise specific; PS, performance status.

► So, what about in patients with HER2-overexpressing non-small cell lung cancer? As I alluded to earlier, T-DXd now has a tumor agnostic approval for unresectable or metastatic HER2-positive IHC 3+ solid tumors. So, this can be considered as a subsequent line therapy in patients with advanced non-small cell lung cancer with 3+ IHC, HER2 overexpression in patients

who have no other treatment options. I think it remains to be seen where this will settle out in the line of treatment in advanced non-small cell lung cancer, but really important, as I mentioned, that these patients should follow the non-driver algorithm, so basically an immunotherapy backbone approach with or without chemotherapy depending on, you know, things like PD-L1

expression, mutational profile. What one would undertake, would when patients without driver mutations in the frontline setting. But again, in the subsequent line setting, I think it's important that we have other options, though I do want to see further data as well as other things that might predict responses as *HER2* amplification.

Adverse Events from HER2-Targeted Therapies: ADCs

T-DM1 in NSCLC (N=49)

Adverse events	Grade 1 N (%)	Grade 2 N (%)	Grade 3 N (%)	Total
Elevated AST or ALT	28 (57)	3 (6)	—	31 (63)
Thrombocytopenia	13 (27)	1 (2)	1 (2)	15 (31)
Fatigue	6 (12)	2 (4)	—	8 (16)
Nausea	14 (29)	—	—	14 (29)
Infusion reaction	2 (4)	5 (10)	—	7 (14)
Anorexia	3 (6)	2 (4)	—	5 (10)
Anemia	1 (1)	3 (6)	1 (2)	5 (10)

NOTE: Treatment-related adverse events with total frequencies of greater than 10%, according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.1 (CTCAE v4.1). There were no grade 4 or 5 adverse events.

Common and important observed AEs

- T-DM1: transaminitis, thrombocytopenia, nausea, fatigue
- T-DXd: nausea, neutropenia, fatigue, anemia, thrombocytopenia, GI upset, left ventricular dysfunction, ILD

T-DXd in NSCLC (N=101)

Preferred Term	T-DXd 5.4 mg/kg Once Every 3 Weeks (n = 101) ^a No. (%)	
	Any Grade	Grade ≥ 3
Nausea	69 (67.3)	4 (4.0)
Neutropenia ^b	43 (42.6)	19 (18.8)
Fatigue ^b	45 (44.6)	8 (7.9)
Decreased appetite	40 (39.6)	2 (2.0)
Anemia ^b	37 (36.6)	11 (10.9)
Vomiting	32 (31.7)	3 (3.0)
Constipation	37 (36.6)	1 (1.0)
Leukopenia ^b	29 (28.7)	5 (5.0)
Thrombocytopenia ^b	28 (27.7)	6 (5.9)
Diarrhea	23 (22.8)	1 (1.0)
Alpecia	22 (21.8)	0
Transaminases increased ^b	22 (21.8)	3 (3.0)

- ▶ Another important, aspect here is surveillance of treatment-related adverse events. So, what are some key treatment-related adverse events with T-DXd and T-DM1, the HER2-targeted ADCs. With T-DM1, as I mentioned, transaminitis, thrombocytopenia, nausea, fatigue. Similarly in T-DXd we can see several of these, what we kind of view as kind of chemotherapy-like AEs, nausea, vomiting, fatigue, decreased appetite. but importantly, we also have to think about, one key side effect, interstitial lung disease, that has been observed in ADC's that incorporate this DXd payload.



LLBI, et al. Cancer Discov. 2020;10(5):674-687. Goto K, et al. J Clin Oncol. 2023;41(31):4852-4863.
 ADC, antibody-drug conjugate; AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; GI, gastrointestinal; HER2, human epidermal growth factor receptor 2; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; T-DM1, ado-trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.

ILD in Advanced NSCLC Treated With T-DXd

- Observed less frequently at 5.4 mg/kg dose (dose that received accelerated FDA approval)

ILD in 5.4 mg/kg arm:

- Median time to onset of 88 days
- 84.6% received steroid treatment
- No patients were retreated
- 61.5% of patients with ILD recovered at time of data cut

Adjudicated Drug-Related ILD

Adjudicated as drug-related ILD	T-DXd 5.4 mg/kg N = 101 ^a	T-DXd 6.4 mg/kg N = 50 ^a
Any grade, n (%)	13 (12.9)	14 (28.0)
Grade 1	4 (4.0)	4 (8.0)
Grade 2	7 (6.9)	9 (18.0)
Grade 3	1 (1.0)	0
Grade 4	0	0
Grade 5	1 (1.0)	1 (2.0)

- ▶ So, a little further detail there. So, this was observed less frequently at the 5.4 mg/kg dose, as I alluded to earlier from the DESTINY-Lung02 study, with the data shown on the right. And just a reminder, updated data from ASCO 2024 showed ILD of 14.9% at the 5.4 mg/kg dose compared to 32% at the 6.4 mg/kg dose. Studies suggest median time to onset of about 88 days, and the majority of patients do receive steroids to treat this ILD. And at least in the studies, no patients were retreated.



Jilani P, et al. WCLC 2023. Abstract MA13.10.
 ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; T-DXd, trastuzumab deruxtecan.

Clinical Management of ILD

- Maintain high index of suspicion, especially in face of new cough, shortness of breath, dyspnea on exertion, fever, etc
- If suspected, STOP T-DXd and initiate steroids unless clear alternative cause identified (PE, arrhythmia, etc.)
- Work-up should include:
 - High resolution chest CT, CBC, blood culture, PFTs, pulse oximetry
 - Consult pulmonology to assist with management
 - Consider bronchoscopy to r/o infection, disease progression, etc
 - Consider ID input if infection suspected
- Differential Diagnosis:
 - Infection, cancer progression, RT pneumonitis, ILD – other cause
- Management:
 - Prednisone (typically 1 mg/kg/d)
- Role for re-initiation of T-DXd if ILD resolves?
 - Data for re-initiation is quite limited
 - Per FDA label, can consider in cases of Grade 1 (asymptomatic) ILD
 - Not recommended if ILD is grade 2+




Powell CA, et al. *ESMO Open*. 2022;7(4):100554. Tarantino P, et al. *JAMA Oncol*. 2021;7(12):1873-1881.
CT, computed tomography; CBC, complete blood count; ID, infectious disease; ILD, interstitial lung disease; PE, pulmonary embolism;
PFT, pulmonary function test; RT, radiotherapy; T-DXd, trastuzumab deruxtecan.

► So, how would I manage ILD if observed? I think it's important to maintain a high index of suspicion. New cough, shortness of breath, dyspnea on exertion, fever, etcetera – high index of suspicion, and if suspected, you must stop T-DXd and initiate steroids promptly. Workup should include a high-resolution chest CT, CBC, blood cultures, PFTs, pulse-ox, typically, we

will also consider consulting pulmonology, as well as consider an infectious disease input because we really want to, you know, utilize an appropriate differential diagnosis here looking at other common things such as infection, cancer progression, radiation-related pneumonitis or ILD of another etiology. As I mentioned earlier, management here is

prednisone, typically 1 mg/kg per day. and what about reinitiating T-DXd if ILD resolves? So, there's very limited data here. Per the FDA label, this can be considered in cases of grade 1 ILD, which by definition is asymptomatic ILD, and it is not recommended, if there are any symptoms or if it's grade 2 or higher ILD. But admittedly, we do need more data in this space.

Clinical Management of ILD



► This is just an algorithm, taken from a publication by Tarantino et al. at *JAMA Oncology* that one can deploy with suspected ADC-related ILD.



Tarantino P, et al. *JAMA Oncol*. 2021;7(12):1873-1881.
 ADC, antibody-drug conjugate; CBC, complete blood count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; KL-6, Krebs von den Lungen 6; LDH, lactate dehydrogenase; PCT, procalcitonin; RT, radiotherapy; SP-A, surfactant protein-A; SP-D, surfactant protein-D.

ADCs: Real-World Experience

- Use of T-DXd in patients with NSCLC requires meticulous proactive monitoring for potential adverse events such as:
 - ILD/pneumonitis
 - Thrombocytopenia
 - Neutropenia
 - Other gastrointestinal/cardiovascular challenges (left ventricular dysfunction)
- Specific protocols to manage these are available and may involve treatment modification or administration of steroids
- Potential complications with concurrent radiation of the chest and ADC therapy

Considerations

- Balancing treatment benefit with treatment-related toxicities
- Reinforcing recommended dosing regimens for HER2-directed therapies
- Incorporating safety and tolerability data from real-world evidence
- Developing strategies to proactively monitor and treat adverse events for support and adherence

► So again, real-world considerations here, use of T-DXd in patients with non-small cell lung cancer really requires meticulous proactive monitoring for adverse events. you know, our more common, chemotherapy-related AEs that I think we're all relatively experienced in managing; nausea, vomiting, fatigue, cytopenias. but then, other things that are specific to trastuzumab-based therapies, such as left ventricular dysfunction. And then, importantly, specific to T-DXd ILD pneumonitis, and maintaining a high index of suspicion for that, and, promptly initiating the steroids if that is suspected.



ENHERTU (fam-trastuzumab deruxtecan-nki). Prescribing information. Daiichi Sankyo, 2022. Swain SM, et al. *Cancer Treat Rev*. 2022;106:102378. Verma S, et al. *Curr Oncol*. 2023;30(4):4329-4350.
 ADC, antibody-drug conjugate; AE, adverse event; HER2, human epidermal growth factor receptor 2; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; T-DXd, trastuzumab deruxtecan.

Chairperson Perspectives

- Monitor for significant adverse events
- Maintain high index of suspicion for ILD
- Promptly initiate steroids
- Do not reinstate T-DXd, unless asymptomatic



ILD, interstitial lung disease; T-DXd, trastuzumab deruxtecan.

► So, what do community clinicians need to keep in mind regarding treatment related adverse events? So, I think it's as I alluded to earlier, I think the key thing is you know, keeping an eye out for significant AEs. Now, if it's things like nausea, vomiting, fatigue, one can consider dose-reductions or spacing the dose needed. But for ILD, one really needs to maintain a high index of suspicion, promptly initiate steroids. And it's really uncommon to consider reinstitution. If it's clinically significant ILD, I would not reinstate T-DXd. However, this can be considered if it's grade 1, so detected on imaging alone without symptoms.

So, let's move forward with a practical application case.

Case Study Patient Presentation and History

Presentation

- A 64 y/o female with newly diagnosed lung adenocarcinoma metastatic to liver and bone presents to your clinic for management
- She is a former ½ PPD smoker for ~10 years, but quit 30 years ago
- She has no other comorbidities and is fit (ECOG 0)
- Brain MRI is negative for intracranial metastases
- Liver biopsy confirms TTF1+ adenocarcinoma consistent with lung primary
- Additional testing reveals PD-L1 80%

Next Step in Care

- Which of the following is the most appropriate next step in care?
 - a) Begin ICI monotherapy +/- platinum-doublet chemotherapy
 - b) Begin platinum-doublet chemotherapy
 - c) Begin afatinib
 - d) Obtain next-generation sequencing (NGS) testing
 - e) Unsure



ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; MRI, magnetic resonance imaging; PPD, pack per day; TTF, thyroid transcription factor.

► So, this is a 64-year-old female with newly diagnosed lung adenocarcinoma, metastatic to liver and bone, presents to clinic for management. She's a former half-pack-a-day smoker for 10 years, but quit 30 years ago, so a very modest smoking history. Quite fit. Liver biopsy unfortunately confirms TTF1 positive adenocarcinoma consistent with lung primary, and additional testing reveals PD-L1 of 80%.

So, which of the following is the most appropriate next step in care? Is it to begin ICI monotherapy with or without platinum doublet chemotherapy, begin platinum-doublet chemotherapy, begin afatinib (an older generation HER2 TKI), obtain next-generation sequencing, or unsure?

Because this patient is fit without significant symptoms,

I would absolutely obtain next-generation sequencing, which is answer choice D. Now, if this patient had had a significant symptoms or you saw LFT increases, you were really worried about them declining quickly, you could begin platinum doublet chemotherapy while awaiting sequencing. But ideally, one waits for sequencing before beginning appropriate therapy.

Case Study Clinical Course

- You obtain additional NGS testing that reveals a pathogenic YVMA duplication (*HER2* exon20 insertion mutation)
- You elect to begin systemic therapy with platinum doublet chemotherapy + ICI, with initial treatment response
- After 8 months, imaging reveals growth of new liver and adrenal lesions, with biopsy confirming TTF1+ adenocarcinoma
- Repeat NGS testing confirms *HER2* exon20 insertion mutation and shows no other actionable mutations
- She otherwise feels well, apart from mild worsening fatigue



HER2, human epidermal growth factor receptor 2; ICI, immune checkpoint inhibitor; NGS, next-generation sequencing; TTF, thyroid transcription factor.

▶ So, in this case you obtain additional next-generation sequencing that reveals a pathogenic YVMA duplication, which is the most *HER2* Exon 20 insertion mutation. You begin systemic therapy with platinum doublet chemo with immunotherapy. After 8 months, of initial response, unfortunately, there is disease progression that's biopsy-confirmed with NGS testing showing the *HER2* Exon 20 insertion. Patient otherwise feels well apart from mild worsening fatigue.

Case Study Audience Question

- What is your best next step in treatment?
 - a) Atezolizumab monotherapy
 - b) Docetaxel
 - c) Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg
 - d) Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg
 - e) Poziotinib



▶ So, in this setting, what would you consider? Atezolizumab monotherapy, docetaxel, trastuzumab deruxtecan 5.4 milligram per kilogram, trastuzumab deruxtecan 6.4 milligram per kilogram dose, or poziotinib (an older *HER2* TKI studied)?

Case Study Conclusion and Rationale for Best/Correct Answer


- Given the strong data from the DESTINY-Lung01 trial and subsequent DESTINY-Lung02 trial, T-DXd is the correct answer
- Specifically, T-DXd 5.4 mg/kg is the correct answer, as this dose was found to be effective with less ILD compared to the 6.4 mg/kg dose in the DESTINY-Lung02 trial

► So, the answer here is T-DXd at 5.4 milligram per kilogram dose. This was the dose studied in the DESTINY-Lung02 trial. And again, important here why that dose over 6.4? More is not always better, and importantly, the efficacy at these two doses was similar with an improved safety profile, specifically less adjudicated ILD at the 5.4 milligram per kilogram dose.



ILD, interstitial lung disease; T-DXd, trastuzumab deruxtecan.

Downloadable Shared Decision-Making Guide



► So importantly, we also have a downloadable shared decision-making guide that accompanies this presentation, some of the things we discussed today on molecular testing, therapy selection, as well as giving details on key points of data on various of the HER2-targeted therapies that we discussed today.



Key Takeaways

- Alterations in HER2 (mutations, gene amplification and protein overexpression) are found in NSCLC
- Broad NGS testing to assess for *HER2* mutations and other actionable driver mutations is recommended at time of diagnosis for patients with advanced NSCLC
- Assessment of *HER2* amplification and HER2 overexpression is not routinely performed as part of initial work-up of advanced NSCLC
- Outside of a clinical trial or individual case-based decision, *HER2* amplification and HER2 overexpression do not currently factor into the frontline management of advanced NSCLC
- Initial management of *HER2*-mutated NSCLC consists of platinum-doublet chemotherapy +/- ICI
- Trastuzumab deruxtecan (T-DXd) is the only HER2-directed therapy with an FDA approval and carries an accelerated approval after progression on prior systemic therapy for *HER2*-mutated NSCLC
- Watch closely for ILD, an important treatment-related adverse event of T-DXd
- If ILD is suspected, discontinue treatment and promptly initiate steroids, with further work-up and management in coordination with pulmonology and possibly infectious disease specialists



HER2, human epidermal growth factor receptor 2; ICI, immune checkpoint inhibitor; ILD, interstitial lung disease; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

► So, what are key takeaways? Number one, alterations in *HER2* mutations, gene amplification, and protein overexpression are all found in non-small cell lung cancer. But the only way you can find these is with broad next-generation sequencing to assess for these mutations. Yes, could you use a more limited platform? You could, but you really want – the gold standard is to deploy broad next-generation sequencing to assess the genomic profile of non-small cell lung cancer, and then appropriately guide therapy from there. I typically use both tissue and liquid testing concurrently in the frontline setting in my practice. Assessment of *HER2* amplification and HER2 overexpression, importantly though, is not routinely performed as part of the initial workup of advanced non-small cell lung cancer,

and outside of a clinical trial or individual case-based decision *HER2* amplification and overexpression do not factor into the frontline management of advanced non-small cell lung cancer. The initial management of *HER2*-mutated non-small cell lung cancer consists of platinum doublet chemotherapy with or without immunotherapy. the addition of immunotherapy should really be as a clinician-based decision, though again, I would steer away from immunotherapy alone in patients with *HER2* mutations. Trastuzumab deruxtecan, or T-DXd, is the only HER2-directed therapy with an FDA approval. It carries an accelerated approval after progression on prior systemic therapy for those with *HER2*-mutated non-small cell lung cancer. T-DXd also has an approval in the subsequent line therapy space for

patients with solid tumors with overexpression defined by IHC 3-plus. So, this is also an option in patients with overexpressing non-small cell lung cancer who have no other alternative systemic therapy. It's important for patients who are on T-DXd to watch closely for ILD, this is an important treatment-related adverse event. And if ILD is suspected, steroid should be started promptly with discontinuation of T-DXd and then in the course, doing further workup to look for other possible etiologies, infection, disease progression, and incorporating important colleagues for that pulmonology, for bronchoscopy lung function assessment, as well as infectious disease colleagues for assessment as well.

So, with that, I want to thank you for your attention and your participation in this activity.

REFERENCES

- A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC (DL-05). ClinicalTrials.gov identifier: NCT05246514. Updated January 19, 2024. <https://clinicaltrials.gov/study/NCT05246514>
- Aggarwal C, Marmarelis ME, Hwang W-T, et al. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non-small-cell lung cancer. *JCO Precis Oncol.* 2023;7:e2300191.
- Aggarwal C, Rolfo CD, Oxnard GR, Gray JE, Sholl LM, Gandara DR. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. *Nat Rev Clin Oncol.* 2021;18(1):56-62.
- ENHERTU (fam-trastuzumab deruxtecan-nxki). Prescribing information. Daiichi Sankyo; 2022.
- Etttinger DS, Wood DE, Riely GJ, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (Version 3.2024). © 2024 National Comprehensive Cancer Network. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org.
- FDA.gov. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. Press release. August 16, 2022. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung>
- FDA.gov. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. April 5, 2024. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2>
- Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. *J Clin Oncol.* 2023;41(31):4852-4863.
- Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. *J Thorac Oncol.* 2020;15(4):628-636.
- Hotta K, Aoe K, Kozuki T, et al. A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. *J Thorac Oncol.* 2018;13(2):273-279.
- Jänne PA, Goto Y, Kubo T, et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): final analysis results of DESTINY-Lung02. *J Clin Oncol.* 2024;42(suppl 16):8543.
- Jänne P, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer: primary results of DESTINY-Lung02. Abstract presented at: World Conference on Lung Cancer; Singapore, September 9-12, 2023. Abstract MA13.10.
- Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-drug conjugates: the last decade. *Pharmaceuticals.* 2020;13:245.
- Li BT, Ahn M-J, Goto K, et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). *J Clin Oncol.* 2022;40(16_suppl):TPS9137.
- Li BT, Michelini F, Misale F, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. *Cancer Discov.* 2020;10(5):674-687.
- Li BT, Planchard D, Goto K, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (NSCLC) with and without brain metastases (BMs): pooled analyses from DESTINY-Lung01 and DESTINY-Lung02. Abstract presented at: European Society For Medical Oncology Congress; Madrid, Spain; October 20-24, 2023. Abstract 1321MO.
- Li BT, Smit EFF, Goto Y, et al. Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC). Abstract presented at: European Society For Medical Oncology Congress; September 16-21, 2021. Abstract LBA45.
- Marks JA, Wilgucki M, Liu SV, Reuss JE. Antibody-drug conjugates in non-small cell lung cancer: emergence of a novel therapeutic class. *Curr Oncol Rep.* 2022;24(12):1829-1841.
- Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol.* 2019;30(8):1321-1328.
- Oh D-Y, Bang Y-J. HER2-targeted therapies - a role beyond breast cancer. *Nat Rev Clin Oncol.* 2020;17(1):33-48.
- Peters S, Stahel R, Bubendorf L, et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. *Clin Cancer Res.* 2019;25(1):64-72.
- Planchard D, Brahmer JR, Yang JC, et al. Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03. Abstract presented at: European Society For Medical Oncology Congress; Madrid, Spain; October 20-24, 2023. Abstract 1507TIP.
- Planchard D, Brahmer JR, Yang JC-H, et al. 1507TIP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03. *Ann Oncol.* 2023;34(suppl 2):S848-S849.
- Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. *ESMO Open.* 2022;7(4):100554.
- Smit EF, Felip E, Uprety D, et al. Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial. Abstract presented at: European Society For Medical Oncology Congress; Paris, France; September 9-13, 2022. Abstract 975P.
- Smit EF, Felip E, Uprety D, et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. *Lancet Oncol.* 2024;25(4):439-454.

REFERENCES

- Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. *J Clin Oncol*. 2020;38(15_suppl):9504.
- Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis, and management. *Cancer Treat Rev*. 2022;106:102378.
- Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. *JAMA Oncol*. 2021;7(12):1873-1881.
- Verma S, Breadner D, Raphael J. 'Targeting' improved outcomes with antibody-drug conjugates in non-small cell lung cancer - an updated review. *Curr Oncol*. 2023;30(4):4329-4350.
- Zhao J, Xia Y. Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review. *JCO Precis Oncol*. 2020;4:411-425.

About AXIS Medical Education, Inc.

AXIS Medical Education, Inc. is a full-service continuing education company that designs and implements live, web-based, and print-based educational activities for healthcare professionals. AXIS provides convenient opportunities to engage learners based on their individual learning preferences through a full spectrum of educational offerings.

The executive leadership of AXIS combines 75 years of experience in adult learning theory, curriculum design/implementation/assessment, continuing education accreditation standards, and medical meeting planning and logistics. Our team has a deep understanding of the governing guidelines overseeing the medical education industry to ensure compliant delivery of all activities.

AXIS employs an experienced team of medical and scientific experts, medical writers, project managers, meeting planners, and logistics professionals. This team is dedicated to meeting the unmet educational needs of healthcare professionals, with the goal of improving patient outcomes.

AXIS believes that partnerships are crucial in our mission to deliver timely, relevant, and high-quality medical education to healthcare professionals. To that end, AXIS partners with other organizations and accredited providers to offer added expertise and assist in expanding access to our educational interventions. AXIS also partners with numerous patient advocacy organizations to provide recommended patient education and caregiver resources in specific disease areas. AXIS finds value in these partnerships because they complement our core clinical curriculum with validated and relevant supplemental resources for busy clinicians and their patients.

The mission of AXIS is to enhance the knowledge, skills, competence, and performance of the interprofessional healthcare team to ensure patients receive quality care, resulting in improved patient outcomes. We engage healthcare professionals in fair-balanced, scientifically rigorous, expert-led certified educational activities designed to foster lifelong learning that is applicable to clinical practice and patient-centered care.

To learn more and to see our current educational offerings, visit us online at www.AXISMedEd.com.

